Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SDCBP | O00560 | 1/20 | 0.39 |
| ▸ | SDC2 | P34741 | 1/20 | 0.39 |
| ▸ | HAT1 | O14929 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405528 | 0.76 | MME (0.51) | NPC1RAB9ALMNAALDH1A1KMT2A | |
| SCHEMBL6412108 | 0.75 | FPR3 (0.46) | ACACBFPR2ALDH1A1 | |
| SCHEMBL3140995 | 0.74 | ACACB (0.48) | ACACBNPC1RAB9AFPR2LMNA | |
| SCHEMBL5049115 | 0.74 | AVPR1A (0.57) | ACACBFPR2ALDH1A1 | |
| SCHEMBL9719691 | 0.73 | MEN1 (0.45) | LMNAALDH1A1KMT2A | |
| SCHEMBL9893002 | 0.71 | ACACB (0.82) | ACACB | |
| SCHEMBL4964750 | 0.70 | EPHX2 (0.46) | NPC1RAB9ALMNAALDH1A1KMT2A | |
| SCHEMBL9891904 | 0.70 | ACACB (0.61) | ACACBNPC1RAB9AFPR2KMT2A | |
| SCHEMBL11581004 | 0.69 | FPR2 (0.72) | NPC1RAB9AFPR2LMNA | |
| SCHEMBL1816209 | 0.69 | ACACB (0.53) | ACACBNPC1RAB9AFPR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773780-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1773780-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012227-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | ACACB 1298/4885NPC1 383/4885RAB9A 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.